Companies: 10,795·Total market cap: $144.5T
Achilles Therapeutics plc

Achilles Therapeutics plc

ACHLNASDAQHealthcare
$1.48
+$0.01(+0.68%)
Market Cap$60828000
P/E Ratio—
52W High$1.51
52W Low$0.63
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Achilles Therapeutics plc (ACHL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ACHL · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.66achl eps ttm · achl earnings per shareEarnings history
PE Ratio (TTM)—achl pe ratio ttm · achl price to earningsPE Ratio deep dive
Revenue (TTM)0.00achl revenue ttm · achl annual revenueFull revenue history
Dividend YieldNo Dividenddoes achl pay dividends · achl dividend yieldDividend history
Shares Outstanding40.0Machl shares outstanding · achl floatShares outstanding history
Next EarningsTBAachl earnings date · achl next earningsEarnings history

Explore Achilles Therapeutics plc Data

achl stock data · financials
Market Cap$60.8Machl market cap · achl valuation
Analyst Forecast$2 · Buy
DividendsNo Dividenddoes achilles therapeutics plc pay dividends · achl dividend yield
Revenue—achilles therapeutics plc annual revenue · achl revenue
EarningsEPS $-1.74+4.40%achl earnings · achl eps
PE Ratio—achl pe ratio · achl price to earnings

Financial Snapshot

Full Financials
FY 2023Revenue$0.00
202120222023
achilles therapeutics plc revenue · achl revenue 2023
FY 2023Net Income-$69.7M▲ +2.12% YoY
202120222023
achilles therapeutics plc net income · achl profit 2023
FY 2023EPS$-1.74▲ +4.40% YoY
202120222023
achl eps · achilles therapeutics plc earnings per share 2023
TTM:Revenue: $0.00Net Income: -$67.0MEPS: $-1.66View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis achl a buy · achl analyst rating
Strong Buy
0
Buy
2
Hold
1
Sell
2
Strong Sell
0
12-Month Price Target
$2.00Low
$1.48Current
$2.00Avg Target35.14% upside
$2.00High
achl price target · achl 12 month forecast

Total: 5 · Buy rate: 40.0%

The ACHL analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $2.00, representing +35.14% upside from the current price of $1.48.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.68%
3M+29.82%
YTD+29.82%
1Y+89.04%
5Y-91.06%

About Achilles Therapeutics plc

CEOIraj Ali
IPO DateMar 31, 2021
Employees204
CountryGB
Websiteachillestx.com

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of…

BiotechnologyHealthcareNASDAQADRGB

what is achilles therapeutics plc · achl stock overview · achilles therapeutics plc company profile · who is achilles therapeutics plc ceo · achl NASDAQ · achilles therapeutics plc headquarters · achilles therapeutics plc business segments

About Stock Overview & Key Data

Achilles Therapeutics plc (ACHL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 31, 2021. As of the latest trading session, ACHL stock price is $1.48, with a market capitalization of $60.8M. The stock has returned +89.04% over the past 12 months and +29.82% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Achilles Therapeutics plc stock is Buy, with an average 12-month price target of $2.00. In fiscal year 2023, Achilles Therapeutics plc reported revenue of — and net income of -$69.7M. For detailed data — including Achilles Therapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Achilles Therapeutics plc (ACHL) stock price is $1.48. The stock is traded on NASDAQ under the ticker symbol ACHL. The 52-week range is $0.63 – $1.51.

ACHL stock priceACHL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice